SOURCES
David L. Hoey, President and CEO of Vaxxas, Cambridge, MA, and Brisbane, Australia.
Pablo Penaloza-MacMaster, PhD, Assistant Professor of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago.
Jasdave Chahal, PhD, Co-founder and Chief Scientist, Tiba Biotech, Cambridge, MA, and Brisbane, Australia.
Vaxart press release: “Vaxart announced positive top-line data from a Phase II clinical trial demonstrating the safety and immunogenicity of its Wuhan S-Only COVID-19 pill vaccine candidate.”
Mark Herr, Spokesman, Vaxart Inc.
The Commonwealth Fund: “Two years of U.S. COVID-19 vaccinations have prevented millions of hospitalizations and deaths.”
The Lancet Infectious Diseases: “Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.”
CDC: COVID Data Tracker, “Fear of Needles and Phobias – Find Ways to Cope.”
Press release from US Specialty Formulations: “Research demonstrates benefits of oral COVID-19 vaccine.”
CanSino Biologics Inc. Statement: “Inside Information.”
Coalition for Innovations in Epidemic Preparedness: Email statement; Press releases: “The race to future-proof coronavirus vaccines.” “Coming in from the cold: Needle-free patch technology for mRNA vaccines aims to end the need for deep-freeze storage and improve access.”
Office of the President: “Statement of Administrative Policy.”
Science: “Mosaic RBD nanoparticles protect against infection by various sarbecoviruses in animal models.”
Caltech press release: “Nanoparticle vaccine protects against a spectrum of COVID-19-causing variants and related viruses.”
US Government Accountability Office. “Operation Warp Speed.”
Press release from Bharat Biotech International Limited: “Bharat Biotech launches iNCOVACC: the world’s first intranasal COVID vaccine for primary vaccination and heterologous booster.”
The Lancet preprints: “Immunogenicity and tolerability of BBV154 (iNCOVACC®), an intranasal SARS-CoV-2 vaccine, compared with intramuscular Covaxin® in healthy adults: A randomized, open-label Phase 3 clinical trial.”
Cell: “Intranasal pediatric parainfluenza virus vaccine against SARS-CoV-2 provides protection in monkeys.”
Press release from the National Institute of Allergy and Infectious Diseases: “NIAID awards additional grants to support development of a pan-coronavirus vaccine.”
CEPI press release: “CEPI and DIOSynVax are working together to develop a broadly protective vaccine against betacoronavirus.”
CDC: “Understanding how COVID-19 vaccines work.”
Natural Immunology: “The T cell immune response against SARS-CoV-2.”
National Institutes of Health: “T cells protect against COVID-19 in the absence of an antibody response.”
PNAS: “Vaccine-induced systemic and mucosal T cell immunity against viral variants of SARS-CoV-2.”
Cell reports: “Pre-existing immunity modulates responses to mRNA boosters.”
University of Minnesota Center for Infectious Disease Research and Policy: “Roadmap for Coronavirus Vaccine Research and Development.”
NIH press release: “2NIAID studies highlight potential of a COVID-10 vaccine for delivery.”
Press release from US Specialty Formulations: “Research demonstrates benefits of oral COVID-19 vaccine.”